News
AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback